Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-02-11

Clinical Trial Update: Rivaroxaban in Idiopathic Membranous Nephropathy [Phase 4]

View source ↗

Summary

Ongoing Phase 4 clinical trial evaluating rivaroxaban for idiopathic membranous nephropathy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xarelto (rivaroxaban)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Idiopathic Membranous Nephropathy | Phase 4 | Status: RECRUITING